Vaccine Discovery Services for SARS-CoV-2

Vaccine research and development has become very urgent with the emergence of new diseases, increased burden of infectious disease, and growing concern regarding vaccine safety. Creative Biolabs has more than a decade of experience and deep expertise in vaccine discovery and development, and we are committed to supporting the vaccine research and development industry with efficient services and cutting-edge technology.

Introduction of SARS-CoV-2

The current 2019 new Coronavirus (SARS-CoV-2) outbreaks in China and its subsequent spread to multiple countries across four continents has triggered a major global health crisis. SARS-CoV-2 is a single positive-stranded RNA virus belonging to the Coronaviridae family, which encompasses the common cold, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS). Like MERS and SARS, SARS-CoV-2 can cause asymptomatic infections or severe acute respiratory diseases, including fever, cough, and shortness of breath. As of 29 January 2020, SARS-CoV-2 has spread to 15 countries, including the Asia-Pacific region, Canada, France, Germany, the United States, and the United Arab Emirates, with 6065 confirmed cases, of which 5997 were reported in China. Although SARS-CoV-2 may be a zoonotic infectious disease, specific animal species and other reservoirs need to be clearly defined. Identifying the source animal species for the outbreak is critical to taking control measures to limit the spread of the disease.

Fig.1 Evolution of a 2019-nCoV virus from bat/unknown animals to humans and spread among humans. (Ramaiah, 2020)

SARS-CoV-2 Vaccine Development Services

SARS-CoV-2 represents a potential epidemic or pandemic threat, but to date, no specific antiviral treatment has been available. For prevention, standard infection control is necessary. As with any new emerging infectious disease, finding new vaccine against the virus is hope.

Creative Biolabs is dedicated to discover and develop vaccines against SARS-CoV-2 diseases and other emerging infectious diseases. Our vaccine discovery and development related services provide cutting-edge technical support to accelerate vaccine research from identification of potential targets to analysis of the immune response and assessment in an infectious challenge model. Creative Biolabs supports the discovery and development of different types of vaccines both at preclinical and clinical stages, including:

• In Silico Vaccine Design for SARS-CoV-2
• Live Attenuated and Killed Vaccine Development Services for SARS-CoV-2
• Recombinant Subunit Vaccine Development Services for SARS-CoV-2
• mRNA Vaccine Development Services for SARS-CoV-2
• Modified Vaccinia Virus Vectored Vaccine Development Services for SARS-CoV-2
• Virus-Like Particles Based Vaccine Development Services for SARS-CoV-2
• SARS-CoV-2 DNA Vaccine
• Formulation Optimization Platform for SARS-CoV-2 Vaccine
• Analysis & Qualification Service for SARS-CoV-2 Vaccine

Our unique combination of expertise in immunology and antiviral vaccine research makes us an ideal partner for your SARS-CoV-2 vaccine discovery. We can help you with each stage of your project, including primary research, antigen development, testing for attenuation, antibody and antigen detection and stability testing. In addition, we also offer a variety of animal disease challenge models to test the safety and efficacy of experimental vaccines in support of market authorization and batch testing. If you have any needs, please feel free to contact us to discuss your requirements.

Reference

1. Ramaiah, A.; Arumugaswami, V. Insights into Cross-species Evolution of Novel Human Coronavirus 2019-nCoV and Defining Immune Determinants for Vaccine Development. BioRxiv. 2020.

For Research Use Only. We do not provide direct services or products for patients.